Bremelanotide + RAAS inhibition therapy
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Disease
Conditions
Kidney Disease
Trial Timeline
Dec 26, 2022 → Apr 26, 2024
NCT ID
NCT05709444About Bremelanotide + RAAS inhibition therapy
Bremelanotide + RAAS inhibition therapy is a phase 2 stage product being developed by Palatin Technologies for Kidney Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05709444. Target conditions include Kidney Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05709444 | Phase 2 | Completed |
Competing Products
20 competing products in Kidney Disease